

Policy Name Uplizna (inebilizumab-cdon)	Policy Number MP-RX-FP-98-23	Scope <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
Service Category <input type="checkbox"/> Anesthesia <input type="checkbox"/> Surgery <input type="checkbox"/> Radiology Procedures <input type="checkbox"/> Pathology and Laboratory Procedures <input type="checkbox"/> Medicine Services and Procedures <input type="checkbox"/> Evaluation and Management Services <input type="checkbox"/> DME/Prosthetics or Supplies <input checked="" type="checkbox"/> Part B DRUG		
Service Description <p>This document addresses the use of Uplizna (inebilizumab-cdon) , a drug approved by the Food and Drug Administration (FDA) for the treatment of neuromyelitis optica spectrum disorder (NMSOD).</p> <p>Background Information</p> <p>This document addresses the use of Uplizna (inebilizumab-cdon), a humanized monoclonal antibody directed against CD19 receptors on B cells. Uplizna treats neuromyelitis optica spectrum disorder (NMSOD) by depleting antibody-secreting plasma cells.</p> <p>NMOSD is a severe autoimmune disease of the central nervous system caused by immune-mediated demyelination and axonal damage predominantly targeting optic nerves and spinal cord. This damage is triggered by antibodies against aquaporin-4 (AQP4), which are considered biomarkers for NMOSD. The disease is characterized by clusters of attacks of optic neuritis or transverse myelitis with partial recovery between attacks. Progressive visual impairment and paralysis may be caused by repeated attacks, so long-term prevention therapy should be offered to all patients. Treatment may include off label immunosuppressive therapies including rituximab, azathioprine, and mycophenolate. Three agents are FDA approved for NMOSD: Uplizna, Enspryng and Soliris. Uplizna has a unique mechanism of action by causing antibody-dependent cellular cytolysis of B-cells. It is given via intravenous infusion once every 6 months.</p> <p>Uplizna can increase the risk of infection, as it is an immunosuppressant. It is contraindicated in those with active hepatitis B (HBV) infection and those with active or untreated latent tuberculosis (TB). Prior to initiation of therapy, all individuals should receive HBV screening, TB screening, and quantitative serum immunoglobulin testing. Individuals should also receive all immunizations according to guidelines prior to initiating therapy.</p> <p>Approved Indications</p> <p>A. neuromyelitis optica spectrum disorder (NMSOD) by depleting antibody-secreting plasma cells</p> <p>Approved Indication 2 Description</p>		

Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope
Uplizna (inebilizumab-cdon)	MP-RX-FP-98-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS	Description
J1823	Injection, inebilizumab-cdon, 1 mg [Uplizna]

ICD-10	Description
G36.0-G36.9	Neuromyelitis optica [Devic]

Medical Necessity Guidelines

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Uplizna (inebilizumab-cdon)

A. Criteria For Initial Approval

I. Individual is 18 years of age or older; AND

II. Individual has a diagnosis of neuromyelitis optica spectrum disorder (NMOSD); AND

III. Documentation is provided that NMOSD is seropositive as confirmed by the presence of anti-aquaporin-4 (AQP4) antibodies; AND

IV. Documentation is provided that individual has a history of at least 1 acute attack or relapse in the last 12 months prior to initiation of therapy;

OR

V. Documentation is provided that individual has a history of at least 2 acute attacks or relapses in the last 24 months prior to initiation of therapy (Cree 2019).

I. Criteria For Continuation of Therapy

I. Documentation is provided that individual has experienced a clinical response (for example, a reduction in the frequency of relapse).

Requests for Uplizna (inebilizumab-cdon) may not be approved if the above criteria are not met and for all other indications.

I. All other indication not included above;

OR

2 II. Individual is using in combination with rituximab, eculizumab, or satralizumab;

OR

III. Individual has active hepatitis B (HBV) infection; OR IV. Individual has active or untreated latent tuberculosis;

OR

V. When the above criteria are not met and for all other indications

J. Authorization Duration

i. Initial and continuation Approval Duration: 1 year

Policy Name	Policy Number	Scope
Uplizna (inebilizumab-cdon)	MP-RX-FP-98-23	<input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth

Limits or Restrictions

A. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Drug	Limit
Uplizna (inebilizumab-cdon) 100 mg/10 mL vial	3 vials (300 mg) every 6 months
Exceptions	
May approve 3 (three) additional vials in the first two weeks of treatment. The total allowed quantity for initiation of therapy is 300 mg once followed by 300 mg two weeks later.	

Reference Information

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2022. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 30, 2022.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
5. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. *Lancet*. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Medical Policy

Healthcare Services Department

Policy Name Uplizna (inebilizumab-cdon)	Policy Number MP-RX-FP-98-23	Scope <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM Multihealth
---	--	--

Policy History

Revision Type	Summary of Changes	P&T Approval Date	MPCC Approval Date
Policy Inception	Elevance Health's Medical Policy adoption.	N/A	11/30/2023

Revised: 11/18/22